BRAF mutation in breast cancer by BRAF V600E mutation-specific antibody

Yoon Yang Jung, Woo Hee Jung, Ja Seung Koo

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The aim of this study is to investigate the BRAF mutation status using BRAF V600E mutation specific antibody in human breast cancer tissue, and discuss its clinical implications. Immunohistochemical staining for BRAF V600E mutation specific antibody was performed using tissue microarrays of 230 cases of breast cancer and 132 cases of triple-negative breast cancer (TNBC). The cases were subdivided into four molecular subtypes, luminal A, luminal B, HER-2 or TNBC, according to the results of ER, PR, HER-2, Ki-67 immunohistochemistry and HER-2 FISH. In TNBC cases, additional immunohistochemical stain for CK5/6, EGFR, claudin 3, claudin 4, claudin 7, E-cadherin, AR, GGT-1, STAT1, and interleukin-8 were performed. TNBC cases were then further subcategorized as follows: Basal-like type (CK5/6 positive and/or EGFR positive), molecular apocrine type (AR positive and/or GGT-1 positive), claudin low type (claudin 3, claudin 4, claudin 7 negative and E-cadherin negative), immune related type (stromal STAT1 positive and IL-8 negative), mixed type (cases consisting of two or more mixed components), and null type (cases that cannot be categorized in any of abovementioned types). In 230 breast cancer, 30 (13.0%) cases showed positivity for BRAF V600E mutation specific antibody, and 17 (7.4%) showed nuclear expression. The nuclear BRAF V600E positivity was associated with ER negativity (P=0.003), PR negativity (P=0.031) and TNBC subtype (P=0.009). In 132 cases of TNBC, 4 (3.0%) cases were positive for BRAF V600E mutation specific antibody, and 10 (7.6%) cases showed nuclear expression. BRAF V600E positivity was most frequently found in the null type, followed by mixed type and basal-like type, and was not found in other subtypes. In TNBC, the nuclear BRAF V600E positivity was associated with lower histological grade (P=0.012). BRAF V600E status did not correlate with the prognosis of breast cancers and TNBC. In conclusion, positivity for BRAF V600E mutation specific antibody was noted in a fraction of breast cancer and TNBC, suggesting the presence of BRAF mutation. BRAF mutation did not have association with clinicopathologic factors of breast cancer.

Original languageEnglish
Pages (from-to)1545-1556
Number of pages12
JournalInternational Journal of Clinical and Experimental Pathology
Volume9
Issue number2
Publication statusPublished - 2016 Jan 1

Fingerprint

Triple Negative Breast Neoplasms
Breast Neoplasms
Mutation
Antibodies
Claudin-3
Claudin-4
Cadherins
Interleukin-8
Claudin-1
Coloring Agents
Immunohistochemistry
Staining and Labeling

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine
  • Histology

Cite this

@article{fa349dbe1f184ea9b3b5be012246639e,
title = "BRAF mutation in breast cancer by BRAF V600E mutation-specific antibody",
abstract = "The aim of this study is to investigate the BRAF mutation status using BRAF V600E mutation specific antibody in human breast cancer tissue, and discuss its clinical implications. Immunohistochemical staining for BRAF V600E mutation specific antibody was performed using tissue microarrays of 230 cases of breast cancer and 132 cases of triple-negative breast cancer (TNBC). The cases were subdivided into four molecular subtypes, luminal A, luminal B, HER-2 or TNBC, according to the results of ER, PR, HER-2, Ki-67 immunohistochemistry and HER-2 FISH. In TNBC cases, additional immunohistochemical stain for CK5/6, EGFR, claudin 3, claudin 4, claudin 7, E-cadherin, AR, GGT-1, STAT1, and interleukin-8 were performed. TNBC cases were then further subcategorized as follows: Basal-like type (CK5/6 positive and/or EGFR positive), molecular apocrine type (AR positive and/or GGT-1 positive), claudin low type (claudin 3, claudin 4, claudin 7 negative and E-cadherin negative), immune related type (stromal STAT1 positive and IL-8 negative), mixed type (cases consisting of two or more mixed components), and null type (cases that cannot be categorized in any of abovementioned types). In 230 breast cancer, 30 (13.0{\%}) cases showed positivity for BRAF V600E mutation specific antibody, and 17 (7.4{\%}) showed nuclear expression. The nuclear BRAF V600E positivity was associated with ER negativity (P=0.003), PR negativity (P=0.031) and TNBC subtype (P=0.009). In 132 cases of TNBC, 4 (3.0{\%}) cases were positive for BRAF V600E mutation specific antibody, and 10 (7.6{\%}) cases showed nuclear expression. BRAF V600E positivity was most frequently found in the null type, followed by mixed type and basal-like type, and was not found in other subtypes. In TNBC, the nuclear BRAF V600E positivity was associated with lower histological grade (P=0.012). BRAF V600E status did not correlate with the prognosis of breast cancers and TNBC. In conclusion, positivity for BRAF V600E mutation specific antibody was noted in a fraction of breast cancer and TNBC, suggesting the presence of BRAF mutation. BRAF mutation did not have association with clinicopathologic factors of breast cancer.",
author = "Jung, {Yoon Yang} and Jung, {Woo Hee} and Koo, {Ja Seung}",
year = "2016",
month = "1",
day = "1",
language = "English",
volume = "9",
pages = "1545--1556",
journal = "International Journal of Clinical and Experimental Pathology",
issn = "1936-2625",
publisher = "e-Century Publishing Corporation",
number = "2",

}

BRAF mutation in breast cancer by BRAF V600E mutation-specific antibody. / Jung, Yoon Yang; Jung, Woo Hee; Koo, Ja Seung.

In: International Journal of Clinical and Experimental Pathology, Vol. 9, No. 2, 01.01.2016, p. 1545-1556.

Research output: Contribution to journalArticle

TY - JOUR

T1 - BRAF mutation in breast cancer by BRAF V600E mutation-specific antibody

AU - Jung, Yoon Yang

AU - Jung, Woo Hee

AU - Koo, Ja Seung

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The aim of this study is to investigate the BRAF mutation status using BRAF V600E mutation specific antibody in human breast cancer tissue, and discuss its clinical implications. Immunohistochemical staining for BRAF V600E mutation specific antibody was performed using tissue microarrays of 230 cases of breast cancer and 132 cases of triple-negative breast cancer (TNBC). The cases were subdivided into four molecular subtypes, luminal A, luminal B, HER-2 or TNBC, according to the results of ER, PR, HER-2, Ki-67 immunohistochemistry and HER-2 FISH. In TNBC cases, additional immunohistochemical stain for CK5/6, EGFR, claudin 3, claudin 4, claudin 7, E-cadherin, AR, GGT-1, STAT1, and interleukin-8 were performed. TNBC cases were then further subcategorized as follows: Basal-like type (CK5/6 positive and/or EGFR positive), molecular apocrine type (AR positive and/or GGT-1 positive), claudin low type (claudin 3, claudin 4, claudin 7 negative and E-cadherin negative), immune related type (stromal STAT1 positive and IL-8 negative), mixed type (cases consisting of two or more mixed components), and null type (cases that cannot be categorized in any of abovementioned types). In 230 breast cancer, 30 (13.0%) cases showed positivity for BRAF V600E mutation specific antibody, and 17 (7.4%) showed nuclear expression. The nuclear BRAF V600E positivity was associated with ER negativity (P=0.003), PR negativity (P=0.031) and TNBC subtype (P=0.009). In 132 cases of TNBC, 4 (3.0%) cases were positive for BRAF V600E mutation specific antibody, and 10 (7.6%) cases showed nuclear expression. BRAF V600E positivity was most frequently found in the null type, followed by mixed type and basal-like type, and was not found in other subtypes. In TNBC, the nuclear BRAF V600E positivity was associated with lower histological grade (P=0.012). BRAF V600E status did not correlate with the prognosis of breast cancers and TNBC. In conclusion, positivity for BRAF V600E mutation specific antibody was noted in a fraction of breast cancer and TNBC, suggesting the presence of BRAF mutation. BRAF mutation did not have association with clinicopathologic factors of breast cancer.

AB - The aim of this study is to investigate the BRAF mutation status using BRAF V600E mutation specific antibody in human breast cancer tissue, and discuss its clinical implications. Immunohistochemical staining for BRAF V600E mutation specific antibody was performed using tissue microarrays of 230 cases of breast cancer and 132 cases of triple-negative breast cancer (TNBC). The cases were subdivided into four molecular subtypes, luminal A, luminal B, HER-2 or TNBC, according to the results of ER, PR, HER-2, Ki-67 immunohistochemistry and HER-2 FISH. In TNBC cases, additional immunohistochemical stain for CK5/6, EGFR, claudin 3, claudin 4, claudin 7, E-cadherin, AR, GGT-1, STAT1, and interleukin-8 were performed. TNBC cases were then further subcategorized as follows: Basal-like type (CK5/6 positive and/or EGFR positive), molecular apocrine type (AR positive and/or GGT-1 positive), claudin low type (claudin 3, claudin 4, claudin 7 negative and E-cadherin negative), immune related type (stromal STAT1 positive and IL-8 negative), mixed type (cases consisting of two or more mixed components), and null type (cases that cannot be categorized in any of abovementioned types). In 230 breast cancer, 30 (13.0%) cases showed positivity for BRAF V600E mutation specific antibody, and 17 (7.4%) showed nuclear expression. The nuclear BRAF V600E positivity was associated with ER negativity (P=0.003), PR negativity (P=0.031) and TNBC subtype (P=0.009). In 132 cases of TNBC, 4 (3.0%) cases were positive for BRAF V600E mutation specific antibody, and 10 (7.6%) cases showed nuclear expression. BRAF V600E positivity was most frequently found in the null type, followed by mixed type and basal-like type, and was not found in other subtypes. In TNBC, the nuclear BRAF V600E positivity was associated with lower histological grade (P=0.012). BRAF V600E status did not correlate with the prognosis of breast cancers and TNBC. In conclusion, positivity for BRAF V600E mutation specific antibody was noted in a fraction of breast cancer and TNBC, suggesting the presence of BRAF mutation. BRAF mutation did not have association with clinicopathologic factors of breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=84967222042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84967222042&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84967222042

VL - 9

SP - 1545

EP - 1556

JO - International Journal of Clinical and Experimental Pathology

JF - International Journal of Clinical and Experimental Pathology

SN - 1936-2625

IS - 2

ER -